Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

R. L H Bolhuis; C. H J Lamers; S. H. Goey; A. M M Eggermont; J. B M Z Trimbos; G. Stoter; A. Lanzavecchia; E. Di Re; S. Miotti; F. Raspagliesi; L. Rivoltini; M. I. Colnaghi

Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

R. L H Bolhuis, C. H J Lamers, S. H. Goey, A. M M Eggermont, J. B M Z Trimbos, G. Stoter, A. Lanzavecchia, E. Di Re, S. Miotti, F. Raspagliesi, L. Rivoltini, M. I. Colnaghi

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

Original language	English
Pages (from-to)	78-81
Number of pages	4
Journal	International Journal of Cancer
Issue number	SUPPL. 7
Publication status	Published - 1992

ASJC Scopus subject areas

Cancer Research
Oncology
Medicine(all)

Cite this

@article{69b3772d2e5146a39144f260950f7507,

title = "Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study",

abstract = "A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.",

author = "Bolhuis, {R. L H} and Lamers, {C. H J} and Goey, {S. H.} and Eggermont, {A. M M} and Trimbos, {J. B M Z} and G. Stoter and A. Lanzavecchia and {Di Re}, E. and S. Miotti and F. Raspagliesi and L. Rivoltini and Colnaghi, {M. I.}",

year = "1992",

language = "English",

pages = "78--81",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "SUPPL. 7",

}

TY - JOUR

T1 - Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes

T2 - A multicenter study

AU - Bolhuis, R. L H

AU - Lamers, C. H J

AU - Goey, S. H.

AU - Eggermont, A. M M

AU - Trimbos, J. B M Z

AU - Stoter, G.

AU - Lanzavecchia, A.

AU - Di Re, E.

AU - Miotti, S.

AU - Raspagliesi, F.

AU - Rivoltini, L.

AU - Colnaghi, M. I.

PY - 1992

Y1 - 1992

N2 - A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

AB - A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

UR - http://www.scopus.com/inward/record.url?scp=0026494425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026494425&partnerID=8YFLogxK

M3 - Article

C2 - 1428412

AN - SCOPUS:0026494425

SN - 0020-7136

SP - 78

EP - 81

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - SUPPL. 7

ER -

Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this